ArticleMolecular psychiatry2022
A multimodal study of a first episode psychosis cohort: potential markers of antipsychotic treatment resistance.
Article in Molecular psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Brain structural abnormalities in treatment-resistant schizophrenia.Molecular psychiatry · 2026Pooled it
- Article
- Impaired Self-Other Voice Discrimination in Patients with Auditory-Verbal Hallucinations and Nonclinical Hallucination Proneness.Schizophrenia bulletin · 2026Article
- Can Sodium Oxybate Mitigate the Symptoms of Schizophrenia?Current neuropharmacology · 2026Review
- Aberrant aging-associated p62 autophagic cascade in biopsied olfactory neuronal cells from patients with psychosis.Schizophrenia (Heidelberg, Germany) · 2025Article
- Macro- and Microstructural Alterations in the Midbrain in Early Psychosis Associates with Clinical Symptom Scores.eNeuro · 2025Article
- Changes in glutamate levels in anterior cingulate cortex following 16 weeks of antipsychotic treatment in antipsychotic-naïve first-episode psychosis patients.Psychological medicine · 2025Article
- Multimodal prediction of the need of clozapine in treatment resistant schizophrenia; a pilot study in first-episode psychosis.Biomarkers in neuropsychiatry · 2024Article
- Leveraging ultra-high field (7T) MRI in psychiatric research.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2024Review
- Reduction of N-acetyl aspartate (NAA) in association with relapse in early-stage psychosis: a 7-Tesla MRS study.Schizophrenia (Heidelberg, Germany) · 2024Article
- Lack of Efficacy of Simvastatin Adjunctive Therapy for Patients with Schizophrenia: A Meta-Analysis of Randomized Controlled Trials.Neuropsychiatric disease and treatment · 2024Article
- A whole-brain neuromark resting-state fMRI analysis of first-episode and early psychosis: Evidence of aberrant cortical-subcortical-cerebellar functional circuitry.NeuroImage. Clinical · 2024Article
- Longitudinal changes in brain metabolites in healthy controls and patients with first episode psychosis: a 7-Tesla MRS study.Molecular psychiatry · 2023Article
- DRESIS: the first comprehensive landscape of drug resistance information.Nucleic acids research · 2023Article
- Central Oxidative Stress and Early Vocational Outcomes in First Episode Psychosis: A 7-Tesla Magnetic Resonance Spectroscopy Study of Glutathione.Schizophrenia bulletin · 2022Article
- A redux of schizophrenia research in 2021.Schizophrenia research · 2022Article
- Paradigm shift on the concept of schizophrenia that matches with both academic and clinical needs.Schizophrenia research · 2022Article
- Sex-specific involvement of the Notch-JAG pathway in social recognition.Translational psychiatry · 2022Article
- Neuroimaging in schizophrenia: A review article.Frontiers in neuroscience · 2022Review
- Ultra-high field neuroimaging in psychosis: A narrative review.Frontiers in psychiatry · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
Abstract
Treatment resistant (TR) psychosis is considered to be a significant cause of disability and functional impairment. Numerous efforts have been made to identify the clinical predictors of TR. However, the exploration of molecular and biological markers is still at an early stage. To understand the TR condition and identify potential molecular and biological markers, we analyzed demographic information, clinical data, structural brain imaging data, and molecular brain imaging data in 7 Tesla magnetic resonance spectroscopy from a first episode psychosis cohort that includes 136 patients. Age, gender, race, smoking status, duration of illness, and antipsychotic dosages were controlled in the analyses. We found that TR patients had a younger age at onset, more hospitalizations, more severe negative symptoms, a reduction in the volumes of the hippocampus (HP) and superior frontal gyrus (SFG), and a reduction in glutathione (GSH) levels in the anterior cingulate cortex (ACC), when compared to non-TR patients. The combination of multiple markers provided a better classification between TR and non-TR patients compared to any individual marker. Our study shows that ACC-GSH, HP and SFG volumes, and age at onset, could potentially be biomarkers for TR diagnosis, while hospitalization and negative symptoms could be used to evaluate the progression of the disease. Multimodal cohorts are essential in obtaining a comprehensive understanding of brain disorders.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.